Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure
| Autor: | Anna Sureda, Maricel Subirá, I Ancín, Salut Brunet, Rodrigo Martino, Albert Altés, Jordi Sierra |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Melphalan
Adult Male medicine.medical_specialty Myeloid Neutropenia Transplantation Conditioning Gastrointestinal Diseases Risk Factors hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Ambulatory Care Humans Transplantation Homologous Transplantation business.industry Incidence (epidemiology) Incidence Siblings Hematopoietic Stem Cell Transplantation Hematology Length of Stay Middle Aged Surgery Fludarabine Hospitalization Regimen Transplantation Isogeneic medicine.anatomical_structure Hematologic Neoplasms Ambulatory Toxicity Feasibility Studies Female business medicine.drug |
| Zdroj: | Bone marrow transplantation. 32(9) |
| ISSN: | 0268-3369 |
| Popis: | Allogeneic stem cell transplantation (allo-SCT) after a reduced-intensity conditioning (RIC) protocol is associated with decreased short-term toxicity. This suggests that the procedure could be performed on an outpatient basis. We analysed the incidence and risk factors of gradeor=2 conditioning-related toxicities (CRTs) as a hallmark for hospital admission, in 41 consecutive patients allografted from an HLA identical sibling after RIC. The RIC regimen consisted of fludarabine plus melphalan for lymphoid malignancies, and fludarabine plus busulphan for myeloid malignancies. In all, 11 patients (27%) did not experience any toxicity. The more frequent CRTs observed were neutropenic fever and gastrointestinal toxicity. The median duration of hospitalisation was 27 (range, 17-50) days. If allo-SCT had been planned as an outpatient procedure and admission indicated only in the case ofor=2 CRTs, the inpatient period would have decreased to 9 (range, 0-33) days (P0.001). No risk factors for CRTs were identified. Allo-SCT after an RIC regimen is a well-tolerated procedure. Our results warrant a prospective pilot trial of nonmyeloablative allo-SCT performed in the outpatient setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|